Investing

Rafael Holdings, Inc. (RFL), a leading global holding company, has released its latest quarterly report, showcasing strong growth despite the significant challenges resulting from the ongoing COVID-19 pandemic and the war in Ukraine. Although the company has implemented various measures to ensure the safety of its workforce and minimize disruptions to operations, the uncertainty around […]

Noteworthy Improvements in Healthcare and Interest Income Rafael Holdings, Inc. (RFL) has released its quarterly report with noteworthy improvements in the company’s healthcare segment, as well as increased interest income from investments. Losses in the healthcare segment have significantly reduced and interest income has grown. The healthcare segment includes the activities of LipoMedix, Barer, Farber,

Rafael Holdings, Inc. Overview Rafael Holdings, Inc. (RFL), a Delaware corporation, is a holding company focusing on investments in clinical and early-stage pharmaceutical companies, including an investment in cancer metabolism-based therapeutics company Cornerstone Pharmaceuticals, Inc. The company also holds a majority equity interest in clinical stage pharmaceutical company LipoMedix Pharmaceuticals Ltd., the activities of the

Rafael Holdings, Inc. (RFL), a company focused on healthcare and real estate, recently reported a decrease in related party rental income as part of their latest quarterly report. The company experienced a drop in related party rental income from approximately 60% for the three months ended April 30, 2022, to 39% for the three months

Rafael Holdings, Inc. Reports Increased Investments in Corporate Bonds and Convertible Note Receivable Rafael Holdings, Inc. (RFL), a company focused on the development and commercialization of therapeutics, diagnostics, and imaging agents, recently released its quarterly report for the period ending April 30, 2023. Among the notable aspects of the report are the company’s increased investment

Rafael Holdings, Inc. (RFL) recently recorded an impairment charge of approximately $79.1 million on its cost method investment in Cornerstone Pharmaceuticals. This impairment charge follows the occurrence of Data Events and covers the total amount of the Company’s cost method investment. Around $17.3 million of the impairment loss was applicable to noncontrolling interests in the

Rafael Holdings, Inc. (RFL) has announced the completed sale of the 520 Property for an aggregate gross purchase price of $49.4 million in its recent quarterly report. After paying off a $15 million mortgage note, commissions, taxes, and other related costs, the company received a net cash amount of approximately $33 million at the closing.

Rafael Holdings increases its stake in LipoMedix Pharmaceuticals Rafael Holdings, Inc. (RFL), a company focused on the development of novel cancer therapies, has recently increased its ownership stake in LipoMedix Pharmaceuticals Ltd. from 84% to 95%. LipoMedix is a clinical-stage pharmaceutical company developing innovative, safe, and effective cancer therapies based on liposome delivery. The increase

Rafael Holdings, Inc. (RFL), a company with interests in clinical and early-stage pharmaceutical firms, displayed robust financial performance in its quarterly report for the period ended April 30, 2023. The company’s available-for-sale securities generated a significant return, increasing from $36.7 million to $66.9 million during the nine-month period. Furthermore, the balance of cash and cash

Renewable Innovations, Inc., a company focused on designing, optimizing, developing, and producing modular, scalable, zero-carbon green renewable solutions, has reported a decrease in revenue for Q1 2023. The revenue for the three months ended February 28, 2023, was $1,098,598, compared to $1,333,245 for the same period in 2022, marking an 18% decrease. Despite the decrease